Regnum Corp. (RGMP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -45 Thousand USD | -99.75% |
| 2021 | -269.83 Thousand USD | -226.38% |
| 2020 | -112.86 Thousand USD | -220.49% |
| 2019 | -35.21 Thousand USD | -970.61% |
| 2018 | 4045.00 USD | 58.63% |
| 2017 | 2550.00 USD | 410.98% |
| 2016 | 275.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -179.32 Thousand USD | -42.96% |
| 2023 Q2 | - USD | 100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 FY | - USD | -99.75% |
| 2022 Q2 | -182.97 Thousand USD | 34.09% |
| 2022 Q1 | -277.6 Thousand USD | -9.13% |
| 2022 Q3 | -160.91 Thousand USD | 12.05% |
| 2022 Q4 | -125.43 Thousand USD | 22.05% |
| 2021 Q1 | -3340.00 USD | -1100.0% |
| 2021 FY | - USD | -226.38% |
| 2021 Q2 | -12.5 Thousand USD | -274.52% |
| 2021 Q4 | -254.37 Thousand USD | -159.18% |
| 2021 Q3 | -98.14 Thousand USD | -684.61% |
| 2020 FY | - USD | -220.49% |
| 2020 Q1 | -67.04 Thousand USD | -1372.52% |
| 2020 Q2 | -37.93 Thousand USD | 43.42% |
| 2020 Q4 | 334.00 USD | 104.06% |
| 2020 Q3 | -8222.00 USD | 78.32% |
| 2019 Q4 | -4553.00 USD | -1885.49% |
| 2019 FY | - USD | -970.61% |
| 2019 Q2 | -7365.00 USD | 68.73% |
| 2019 Q1 | -23.55 Thousand USD | -17809.02% |
| 2019 Q3 | 255.00 USD | 103.46% |
| 2018 Q2 | 1706.00 USD | -7.38% |
| 2018 Q3 | 364.00 USD | -78.66% |
| 2018 FY | - USD | 58.63% |
| 2018 Q4 | 133.00 USD | -63.46% |
| 2018 Q1 | 1842.00 USD | 287.79% |
| 2017 Q3 | 707.00 USD | -68.83% |
| 2017 Q1 | -900.00 USD | 0.0% |
| 2017 Q4 | 475.00 USD | -32.81% |
| 2017 Q2 | 2268.00 USD | 352.0% |
| 2017 FY | - USD | 410.98% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.37 Million USD | 99.741% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 92.884% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 108.532% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 87.746% |
| Qrons Inc. | -40.08 Thousand USD | -12.273% |
| Rebus Holdings, Inc. | -951 Thousand USD | 95.268% |
| Skye Bioscience, Inc. | -13.54 Million USD | 99.668% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.048% |
| Adynxx, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 99.919% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 99.716% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 98.841% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.937% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 99.241% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 81.183% |
| SQZ Biotechnologies Company | -64.14 Million USD | 99.93% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 98.298% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 97.07% |
| Mesoblast Limited | -62.38 Million USD | 99.928% |
| Marizyme, Inc. | -34.28 Million USD | 99.869% |
| Genus plc | 73.7 Million USD | 100.061% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 99.319% |
| Pharming Group N.V. | 9.87 Million USD | 100.456% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 96.975% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 98.731% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 99.487% |
| ContraFect Corporation | -64.99 Million USD | 99.931% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 99.006% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 96.79% |
| IMV Inc. | -35.52 Million USD | 99.873% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 98.064% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 91.314% |
| ONE Bio Corp. | 13.61 Million USD | 100.331% |
| Accustem Sciences Inc. | -3.74 Million USD | 98.799% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 99.907% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 96.449% |
| Q BioMed Inc. | -617.62 Thousand USD | 92.714% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 101.26% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 98.03% |
| Biomind Labs Inc. | -1.03 Million USD | 95.65% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 99.886% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 98.444% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 99.372% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 769.244% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -80.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 98.201% |
| GB Sciences, Inc. | -1.41 Million USD | 96.831% |
| Alpha Cognition Inc. | -9.7 Million USD | 99.536% |
| HST Global, Inc. | -5303.00 USD | -748.576% |
| CSL Limited | 4.78 Billion USD | 100.001% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 97.812% |
| Halberd Corporation | -74.27 Thousand USD | 39.418% |
| Enzolytics Inc. | -2.12 Million USD | 97.879% |
| Agentix Corp. | -1.37 Million USD | 96.72% |
| Resverlogix Corp. | -11.74 Million USD | 99.617% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 98.531% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 99.979% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 103.698% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 100.508% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 96.998% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 111.878% |
| AVAX Technologies, Inc. | -6.11 Million USD | 99.264% |
| Zenith Capital Corp. | -8.6 Million USD | 99.477% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.982% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -158.309% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 98.161% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 74.435% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 97.657% |
| Kadimastem Ltd | -2.62 Million USD | 98.285% |
| Helix BioMedix, Inc. | -1.04 Million USD | 95.699% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 97.429% |
| BioStem Technologies, Inc. | -7.55 Million USD | 99.404% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 75.15% |
| LadRx Corporation | 412.28 Thousand USD | 110.915% |
| Cell Source, Inc. | -4.27 Million USD | 98.947% |
| Regen BioPharma, Inc. | 1.46 Million USD | 103.07% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 95.197% |
| NovAccess Global Inc. | -1.03 Million USD | 95.651% |
| Affymax, Inc. | -14.29 Million USD | 99.685% |
| Itoco Inc. | -1.86 Million USD | 97.592% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 88.146% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 95.968% |
| Mobile Lads Corp. | -2.24 Million USD | 97.992% |
| CytoDyn Inc. | -18.02 Million USD | 99.75% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 43.059% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -267.978% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 90.735% |
| SYBLEU INC | -141.57 Thousand USD | 68.214% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 95.763% |
| International Stem Cell Corporation | 202 Thousand USD | 122.277% |
| Bioxytran, Inc. | -3.82 Million USD | 98.822% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 14.514% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 98.172% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 99.875% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 98.356% |
| Neutra Corp. | -181.24 Thousand USD | 75.172% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 99.777% |
| PureTech Health plc | -11.62 Million USD | 99.613% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 99.777% |
| IXICO plc | -707 Thousand USD | 93.635% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 99.414% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 99.907% |
| CSL Limited | 4.73 Billion USD | 100.001% |
| Cellectis S.A. | -92.63 Million USD | 99.951% |